We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Cancer Treatment and Genetic Predisposition Drive Subsequent Neoplasm Risk in Childhood Cancer Survivors

MedXY Editorial Team•Oct 1, 2025•Clinical Updates
cancer treatmentchildhood cancergenetic predispositionsubsequent neoplasms

Highlight

  • Cancer treatments, particularly radiotherapy, and genetic predisposition significantly contribute to the risk of subsequent neoplasms (SNs) in childhood cancer survivors.
  • Polygenic risk scores (PRSs) quantify genetic susceptibility, showing notable impact on SN risk, especially for thyroid cancer.
  • Lifestyle factors such as smoking, alcohol, obesity, physical activity, and diet have minimal influence on SN risk compared to genetic and treatment-related factors.
  • These findings emphasize the need for tailored risk assessment and surveillance strategies incorporating both treatment exposure and genetic risk.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Adolescent Peer Influences on Mental Disorder Risk: Diagnoses and Genetic Predispositions in Population CohortsPeer networks in adolescence, especially in upper secondary school, significantly influence the risk trajectory for mental disorders through peers’ diagnosed conditions and genetic predispositions, with subtype-specific and cross-disoJul 30, 2026Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based ReviewMedicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effectiveJul 17, 2026Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized TrialsTwo large randomized trials reveal that Helicobacter pylori infection elevates colorectal cancer risk, particularly in individuals with specific bacterial virulence factors or high genetic susceptibility, and that eradication treatment may Jul 1, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma
A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.
May 8, 2026
Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer SurvivorsThis article examines the CHIIP study, a randomized clinical trial evaluating whether survivorship care plan-based counseling improves cardiovascular risk factor control in childhood cancer survivors. Findings suggest that while documentatiFeb 24, 2026
RNA Cancer Vaccines: Revolutionary Advances Bringing Hope for 2029 Clinical UseRNA cancer vaccines are emerging as powerful tools against hard-to-treat cancers, with breakthroughs in melanoma, pancreatic, and brain cancers showing promise for widespread clinical adoption by 2029.Nov 14, 2025